All Phenotypes Dusp11<Gt(BB0198)Wtsi> MGI Mouse

increased susceptibility to induced morbidity/mortality ( J:301503 )

• only 20% of mice survive at 24-120 h after LPS treatment, whereas wild-type controls do not die until 48 h after LPS injection and >40% of them are still alive at 120 h

immune system phenotype ( J:301503 )

N	• at 5-12 weeks of age, mice exhibit normal immune cell development relative to wild-type controls

abnormal macrophage activation involved in immune response ( J:301503 )

• bone marrow-derived macrophages (BMDMs) show enhanced LPS-induced macrophage activation with significantly higher levels of TGF-beta-activated kinase 1 (TAK1) phosphorylation and cytokine production relative to LPS-treated wild-type BMDMs

increased macrophage cytokine production ( J:301503 )

• upon LPS stimulation, BMDMs show a significantly higher production of IL-1beta, TNF and IL-6 relative to wild-type BMDMs

increased circulating interleukin-1 beta level ( J:301503 )

• at 6 h after LPS injection, serum IL-1beta levels are significantly higher than those in wild-type controls

increased circulating interleukin-6 level ( J:301503 )

• at 6 h after LPS injection, serum IL-6 levels are significantly higher than those in wild-type controls

increased circulating tumor necrosis factor level ( J:301503 )

• at 6 h after LPS injection, serum TNF levels are significantly higher than those in wild-type controls

increased susceptibility to endotoxin shock ( J:301503 )

• mice exhibit increased susceptibility to LPS-induced endotoxic shock, with significantly higher serum levels of IL-1beta, TNF and IL-6 at 6 h after i.p. LPS injection (15mg/kg body weight) relative to LPS-treated wild-type controls

• only 20% of mice survive at 24-120 h after LPS treatment, whereas wild-type controls do not die until 48 h and >40% of them are still alive at 120 h after LPS injection